NCT04801095 is a Phase 1 clinical trial of WM-S1-030 in Advanced Solid Tumor, sponsored by Wellmarker Bio.

Who is sponsoring NCT04801095?

NCT04801095 is sponsored by Wellmarker Bio.

What drugs are being tested in NCT04801095?

Interventions in NCT04801095: WM-S1-030.

What condition does NCT04801095 study?

NCT04801095 studies Advanced Solid Tumor, Metastatic Solid Tumor, Colorectal Cancer, Lung Cancer, Pancreatic Cancer, Cholangiocarcinoma, Head and Neck Cancer.

Is NCT04801095 still recruiting?

NCT04801095 is currently status unknown. Last updated 16 September 2022.

Last reviewed 2022-09-16 · How we verify

NCT04801095

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase I Study of WM-S1-030 in Patients With Advanced Solid Tumors

Status unknown Phase 1 Last updated 16 September 2022

What this trial tests

Phase 1 trial testing WM-S1-030 in Advanced Solid Tumor in 100 participants. Status unknown.

Timeline

14 July 2021

Primary endpoint
8 August 2025

8 August 2025

Quick facts

Lead sponsor	Wellmarker Bio
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	14 July 2021
Primary completion	8 August 2025
Estimated completion	8 August 2025
Sites	6 locations across Australia, South Korea

Drugs / interventions tested

WM-S1-030 — full drug profile →

Conditions studied

Advanced Solid Tumor — all drugs for Advanced Solid Tumor →
Metastatic Solid Tumor — all drugs for Metastatic Solid Tumor →
Colorectal Cancer — all drugs for Colorectal Cancer →
Lung Cancer — all drugs for Lung Cancer →

Sponsor

Wellmarker Bio — full company profile →

Who can join

18 and older, any sex, with Advanced Solid Tumor or Metastatic Solid Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of WM-S1-030 in patients with advanced solid tumors.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Current and Emerging Therapeutic Targets for the Treatment of Cholangiocarcinoma: An Updated Review.
Hadfield MJ, DeCarli K, Bash K, Sun G, et al · · 2023 · cited 12× · PMID 38203714 · DOI 10.3390/ijms25010543
Targeting isoforms of RON kinase (MST1R) drives antitumor efficacy.
Kim J, Koh DI, Lee M, Park YS, et al · · 2023 · cited 5× · PMID 37926711 · DOI 10.1038/s41418-023-01235-9
A review of molecularly targeted therapy in biliary tract carcinoma: what is the next step?
Aimar G, Paratore C, Zichi C, Marino D, et al · · 2021 · cited 3× · PMID 36045702 · DOI 10.37349/etat.2021.00056

Verify or expand the search:

Other recruiting trials for Advanced Solid Tumor

Currently open trials in the same condition.

NCT07300943 — Study in Advanced Solid Tumor Patients · Phase 1, PHASE2 · recruiting
NCT07304128 — A Study of PLB-002 in Advanced Solid Tumors · Phase 1 · recruiting
NCT07213830 — A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity · Phase 1, PHASE2 · recruiting
NCT07226349 — A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors · Phase 1 · recruiting
NCT07222267 — An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Soli · Phase 1 · recruiting

Other Wellmarker Bio trials

Trials by the same sponsor.

NCT05872867 — Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (MK-3475-E90 · Phase 1 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04801095 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Wellmarker Bio
Last refreshed: 16 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04801095.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing